Exposure to misleading information can distort memory for past events (misinformation effect). Here, we show that providing individuals with a simple warning about the threat of misinformation significantly reduces the misinformation effect, regardless of whether warnings are provided proactively (before exposure to misinformation) or retroactively (after exposure to misinformation). Liquibid-D Tablet, Extended Release 12 Hr Side Effects by Likelihood and Severity RARE side effects. If experienced, these tend to have a Severe expression. Precautions, drug interactions.
The FDA Alert(s) below may be specifically about Liquibid or relate to a group or class of drugs which include Liquibid (guaifenesin). Together 2 6 7 – store files text and images.
MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com. Following is a list of possible medication recalls, market withdrawals, alerts and warnings. For the latest FDA MedWatch alerts, go here.
Recent FDA Alert(s) for guaifenesin
FDA Advises Consumers Not to Use Rompe Pecho Cough Syrup
Oct 11, 2019
Audience: Consumers
October 11, 2019 -- FDA advises consumers not to use Rompe Pecho EX and Rompe Pecho CF cough syrups distributed by Efficient Laboratories, Inc., Miami, Florida, due to microbial contamination risks. These are over-the-counter medicines for children six years and older. FDA recommends consumers stop using these medicines and dispose of them. These contaminated cough medicines could potentially cause illness.
On October 9, 2019, FDA recommended that Efficient Laboratories recall Rompe Pecho EX and Rompe Pecho CF cough syrups. To date, the company has not taken action to remove these potentially dangerous medicines from the market.
FDA is not aware of any reports of adverse events associated with these medicines at this time. Consumers who use Rompe Pecho EX and Rompe Pecho CF cough syrups and have concerns should contact their health care professional.
FDA encourages health care professionals and patients to report adverse events or quality problems experienced with the use of any medication to FDA's MedWatch Adverse Event Reporting program:
- Complete and submit the report online; or
- Download and complete the form, then submit it via fax at 1-800-FDA-0178
Source: FDA
Children's Guaifenesin Grape Liquid and Guaifenesin DM Cherry Liquid by Perrigo Company: Recall - Potential Defect with Dosage Cup
Jan 13, 2016
Audience: Consumer
Including store brands:
- Sunmark
- Rite-Aid
- Topcare
- Kroger
- GoodSense
- Dollar General
- Care One
- CVS
ISSUE: Perrigo Company announced that, following the recent recall of certain dosing cups by its supplier, it has initiated a voluntary product recall in the US to the retail level of 2 batches of its children's guaifenesin grape liquid (100mg/5 mL) and 3 batches of its children's guaifenesin DM cherry liquid (100mg guaifenesin and 5mg dextromethorphan HBr/ 5 ml) sold in 4 oz. bottles with dosage cup in a box under multiple store brand product names. Some packages contain an oral dosing cup with incorrect dose markings. See the press release for affected label and lot numbers.
At risk populations such as those who are poor metabolizers of dextromethorphan may experience an overdose by a factor of 3, if incorrect measuring levels are used.
Consumers should be aware that an overdose of Guaifenesin DM may cause hyper excitability, rapid eye movements, changes in muscle reflexes, ataxia, dystonia, hallucinations, stupor, and coma. Other effects have included nausea, vomiting, tachycardia, irregular heartbeat, seizures, respiratory depression, and death. Small children who are poor metabolizers of dextromethorphan and use the product regularly over a period of several days at the mistaken dose, may develop cumulative toxicity. Moreover, adverse reactions to guaifenesin when given in high or excessive dosage may include nausea/vomiting, diarrhea, and/or abdominal pain. Therefore, an extreme overdose in an at risk population may need medical intervention, but in most cases adverse health consequences are temporary and reversible.
BACKGROUND: These recalled products are sold by distributors nationwide and distributed through retail stores.
RECOMMENDATION: Gastric decontamination is recommended after acute ingestion of greater than 10 mg/kg, if administered soon after ingestion.
Consumers that have product with the corresponding labels and batch numbers listed in the Press Release should discard the dosing device and product and may call Perrigo, toll free, Monday through Friday from 8:00 AM to 10:00 PM EST, at 1-888-345-0479, or visit mucusreliefrecall.com. Consumers should contact their physician or healthcare provider if they have any questions, or if they or their children experience any problem that could possibly be related to this drug product.
Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
- Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[01/11/2016 - Press Release - Perrigo]
Reese Pharmaceutical Company OTC Products: Recall - Mislabeled Guaifenesin Tablets
Dec 13, 2010
Audience: Consumer, Pharmacist
Refenesen Expectorant (guaifenesin 200 mg tablets)
Select Brand Mucus Relief Expectorant (guaifenesin 200 mg)
QC Medifin Expectorant (guaifenesin 200 mg)
Leader Cough Tabs Expectorant (guaifenesin 200 mg)
ISSUE: Reese Pharmaceutical Company has voluntarily recalled lot# 091612 only in 60-count size bottles identified under four different brand names: Refenesen Expectorant (guaifenesin 200 mg tablets), Select Brand Mucus Relief Expectorant (guaifenesin 200 mg), QC Medifin Expectorant (guaifenesin 200 mg), and Leader Cough Tabs Expectorant (guaifenesin 200 mg) because cold decongestant tablets (containing Acetaminophen 325 mg, Phenylephrine 5 mg & Chlorpheniramine Maleate 2 mg) were mislabeled as containing only 200mg Guaifenesin tablets.
BACKGROUND: The mislabeled product does not warn consumers that Acetaminophen may cause liver damage. Ingesting high doses of Acetaminophen can potentially cause severe liver damage. The likelihood of acute liver damage is higher among consumers with pre-existing liver disease and those who drink three or more alcoholic drinks per day. Overdose may specially occur if consumers are also taking other cold/cough products that contain Acetaminophen in addition to the mislabeled product. Contraindications for Phenylephrine are high-blood pressure, poor blood flow to the extremities, and patients on antidepressants known as MAO Inhibitors. Furthermore, products that contain Phenylephrine should be used with caution in patients with high blood pressure, diabetes, heart disease, increased intraocular pressure, hyperthyroidism, or enlarged prostate. Consumers who are allergic to any of the ingredients or who have narrow angle glaucoma, or are pregnant or nursing mothers, also should not take the product.
RECOMMENDATION: Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
Liquibid Video Exposure And Effects 1 0 66 Inches
- Complete and submit the report Online: www.accessdata.fda.gov/scripts/medwatch/index.cfm
- Download form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
[12/08/2010 - Press Release - Reese Pharmaceutical]
Guaifenesin (Unapproved) Timed-Release Drug Products
May 25, 2007
Audience: Consumers, healthcare professionals
[Posted 05/25/2007] FDA informed consumers and healthcare professionals of its intent to take action against companies that market unapproved timed-release dosage form of guaifenesin products, a substance commonly used in medicines to relieve cough and cold symptoms by stimulating removal of mucous from the lungs. These dosage forms are often described as extended-release, long-acting or sustained-release products that release their active ingredients over an extended period of time, reducing the number of doses needed per day. Approximately 20 firms make unapproved timed-release products containing guaifenesin that have not undergone FDA review for safety and efficacy. Mucinex, Mucinex-D, Mucinex-DM, and Humibid are the only FDA approved timed-release guaifenesin (single ingredient or combination) products. Companies marketing unapproved products containing guaifenesin in timed-release form are expected to stop manufacturing them within 90 days and must cease shipping them in interstate commerce within 180 days. This action does not affect products containing guaifenesin in immediate release form.[May 25, 2007 - News Release - FDA]
The previously rumored Exposure X6 photo editing software is now available (see pricing and update options). A free trial is available here. Here are some of the new features:
- New GPU optimization leverages the full power of your computer hardware to dramatically speed up image processing.
- One-click automatic adjustments select optimized values for white balance, exposure, haze level, contrast, and tone.
- Enhanced shadows and highlight processing is now more reliable, consistent, and accurate.
- New profile guided noise reduction eliminates noise based on camera sensor characteristics.
- The Advanced Color Editor builds on Exposure's innovative 3D masking to enable vastly greater control of color modifications. Perform sophisticated color replacements in just a few clicks.
- Updated user interface provides a refined, modern aesthetic.
- New haze level slider counteracts contrast decreases caused by atmospheric haze.
- New mask visualization options.
- DNG converter integration enables conversion to DNG format manually or automatically when copying from a camera card.
- The new manual complements our extensive video and in-product documentation.
Press release:
Exposure Software Announces Exposure X6, Image Editing Software for Creative Photographers
Exposure X6 features dramatic speed improvement, one-click automatic adjustments, advanced color replacement, innovative shadow/highlight and noise reduction processing, and more
Raleigh, NC (September 15, 2020) – Exposure Software, formerly known as Alien Skin Software, today announced the release of Exposure X6, the newest version of their award-winning RAW photo editor for creative photographers. Exposure is a standalone image editor that handles a full photography workflow. It includes plug-in support that enables Exposure's advanced editing and creative effects in Adobe Photoshop or Lightroom.
New in Exposure X6 is advanced GPU optimization, which dramatically speeds up image processing. GPU support works in concert with Exposure's existing multi-core optimization to enable Exposure to leverage the full power of modern computer hardware. Many frequently used editing operations have been sped up by a factor of three on typical GPU hardware. This improved performance enables editing at greatly improved speeds, reducing distraction so photographers can focus on creativity.
'The introduction of GPU support in Exposure X6 enabled us to achieve amazing speed and image processing quality improvements,' said Finley Lee, CEO of Exposure Software. 'This further advances our goal of making Exposure the best available image editor for creative photography.'
New automatic adjustments select optimized values for the most frequently used controls in a single click, freeing time for creative editing. They can even be applied in batch to significantly ease the time spent editing large photoshoots. Exposure's new automatic adjustments include the following:
- Auto White Balance adjusts white balance based on camera metadata. Corrects for tungsten, artificial, shade, and sunlight illuminant scenes.
- Auto Exposure sets image exposure for both under and overexposed images.
- Auto Haze Level changes the level of atmospheric haze present in the image. This is particularly useful for backlit subjects and images shot into the sun.
- Auto Dynamic Contrast lowers and raises the overall image contrast without changing saturation or hue.
- Auto Tone sets values for Blacks, Shadows, Highlights, and Whites sliders that affect overall image tone.
Using an innovative tonal-zone approach, Exposure's redesigned shadows and highlights controls are more reliable, consistent, and accurate. These intuitive controls are particularly adept at recovering lost details in the highlight and shadow areas. The adjustments are applied intelligently to prevent unwanted color casts or hue shifts. They are exceptionally well-suited in preserving high or low key scenes.
Exposure's new profile guided noise reduction capability reduces noise based on camera sensor characteristics, ISO, and estimated electronic noise. Luminance and chrominance noise can be reduced independently. The smoothing option applies an adaptive noise-sensitive algorithm which preserves sharp edges while further reducing noise.
The new Advanced Color Editor builds on Exposure's innovative 3D color masking to enable vastly greater control of color modifications. For example, a model's blue dress can be changed to red in just a few clicks. Photographers can select source and target colors based on luminance, hue, and saturation attributes. It is even possible to select multiple color replacement mappings and save them as a preset to be reused.
Additional enhancements to Exposure include the following:
- Updated user interface provides a refined, modern aesthetic
- New haze level slider, for counteracting the decrease in contrast caused by atmospheric haze. It can also add haze as a creative effect.
- Customization of the hue and opacity of the selection mask overlay.
- Optional black background for the mask to view selected pixels without distraction.
- Optional luminance or saturation background for the selection mask, which helps visualize the mask region when adjusting luminance or saturation constraints.
- DNG converter integration enables conversion of RAW photos to DNG format using Adobe's DNG Converter software. Conversion can be performed automatically when copying photos from a camera card, or manually invoked from a photo's thumbnail view.
About Exposure
Exposure began in 2005 as a film simulation plug-in for Photoshop, and was immediately embraced by digital photographers of all genres seeking to recapture the organic look of film. Over the years, Exposure became a legend among plug-ins, and evolved into a standalone full-featured editing and organizing solution for creative photographers.
Liquibid Video Exposure And Effects 1 0 66 Degrees
Pricing and Availability
Exposure X6 is available now from https://exposure.software for $119. Upgrade pricing is available to owners of previous versions of Exposure for $89. Additionally, anyone who purchased Exposure X5 on or after July 15, 2020 will automatically receive a free upgrade to Exposure X6.
Exposure X6 is also available in the Exposure X6 Bundle. This integrated collection combines Exposure with Exposure Software's award-winning Blow Up and Snap Art tools to add high-quality upsizing and natural media special effects. It is available for $149. Owners of one or more of the current apps in the Exposure X6 Bundle can purchase for $99.
A 30-day fully-featured free trial of Exposure is available. Visit https://exposure.software to learn more and download the trial.
Host Requirements
Exposure X6 may be used as a standalone program or as a set of plug-ins. When used as a set of plug-ins, it requires one of the following host applications:
- Adobe Photoshop CS6 or Adobe Photoshop CC 2015 or newer
- Adobe Lightroom 6 or Adobe Lightroom CC 2015 or newer
System Requirements
Mac
- OS X 10.11 El Capitan or newer
- Intel Core 2 processor or newer
- Monitor with 1280 x 768 resolution or greater
- 8GB RAM minimum, 16GB recommended
- For GPU support, a recent (2015 or later) Metal compatible GPU with 2GB RAM is recommended
Windows
- Windows 10 64-bit or newer
- Intel Core 2 processor or newer
- Monitor with 1280 x 768 resolution or greater
- 8GB RAM minimum, 16GB recommended
- For GPU support, a recent (2015 or later) OpenCL compatible GPU with 2GB RAM is recommended
Related posts:
